EAU Guidelines on penile curvature

1. Musitelli S, Bossi M, Jallous H. A brief historical survey of “Peyronie’s disease”. J Sex Med 2008; 5(7): 1737–1346.

2. Oxford Centre for Evidence-Based Medicine Levels of Evidence (May 2009). Produced by Phillips B, Ball C, Sackett D et al since November 1998. Updated by Jeremy Howick March 2009.

3. Atkins D, Best D, Briss PA et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004; 328(7454): 1490.

4. Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336(7650): 924–926.

5. Guyatt GH, Oxman AD, Kunz R et al. GRADE Working Group. Going from evidence to recommendations. BMJ 2008; 336(7652): 1049–1051.

6. Yachia D, Beyar M, Aridogan IA et al. The incidence of congenital penile curvature. J Urol 1993; 150 (5 Pt 1): 1478–1479.

7. Montag S, Palmer LS. Abnormalities of penile curvature: chordee and penile torsion. ScientificWorld­Journal 2011; 11: 1470–1478.

8. Darewicz B, Kudelski J, Szynaka B et al. Ultra­structure of the tunica albuginea in congenital penile curvature. J Urol 2001; 166(5): 1766–1768.

9. Baskin LS, Duckett JW, Lue TF. Penile curvature. Urology 1996; 48(3): 347–356.

10. Catuogno C, Romano G. Androstanolone treatment for congenital penile curvature. Eur Urol 2001; 39 (Suppl 2): 28–32.

11. Nesbit R. Congenital curvature of the phallus: Report of three cases with description of corrective operation. J Urol 1965; 93: 230–232.

12. Bar Yosef Y, Binyamini J, Matzkin H et al. Midline dorsal plication technique for penile curvature repair. J Urol 2004; 172 (4 Pt 1): 1368–1369.

13. Hayashi Y, Kojima Y, Mizuno K et al. Modified technique of dorsal plication for penile curvature with or without hypospadias. Urology 2002; 59(4): 584–586.

14. Ebbehoj J, Metz P. Congenital penile angulation. Br J Urol 1987; 60(3): 264–266.

15. Badawy H, Morsi H. Long-term followup of dermal grafts for repair of severe penile curvature. J Urol 2008; 180 (4 Suppl): 1842–1845.

16. Schwarzer U, Sommer F, Klotz T et al. The prevalence of Peyronie’s disease: results of a large survey. BJU Int 2001; 88(7): 727–730.

17. Rhoden EL, Teloken C, Ting HY et al. Prevalence of Peyronie’s disease in men over 50-y-old from Sout­hern Brazil. Int J Impot Res 2001; 13(5): 291–293.

18. Mulhall JP, Creech SD, Boorjian SA et al. Subjec­tive and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol 2004; 171 (6 Pt 1): 2350–2353.

19. La Pera G, Pescatori ES, Calabrese M et al. Peyronie’s disease: prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50-69 years. Eur Urol 2001; 40: 525–530.

20. Kumar B, Narang T, Gupta S et al. A clinico-aetiological and ultrasonographic study of Peyronie’s disease. Sex Health 2006; 3(2): 113–118.

21. Lindsay MB, Schain DM, Grambsch P et al. The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991; 146(4): 1007–1009.

22. Sommer F, Schwarzer U, Wassmer G et al. Epide­miology of Peyronie’s disease. Int J Impot Res 2002; 14(5): 379–383.

23. Devine CJ Jr., Somers KD, Jordan SG et al. Pro­posal: trauma as the cause of the Peyronie’s lesion. J Urol 1997; 157: 285–290.

24. Jarow JP, Lowe FC. Penile trauma: an etiologic factor in Peyronie’s disease and erectile dysfunction. J Urol 1997; 158(4): 1388–1390.

25. Gonzalez-Cadavid NF, Rajfer J. Mechanisms of Disease: new insights into the cellular and molecular pathology of Peyronie’s disease. Nat Clin Pract Urol 2005; 2(6): 291–297.

26. Rhoden EL, Riedner CE, Fuchs SC et al. A cross-sectional study for the analysis of clinical, sexual and laboratory conditions associated to Peyronie’s disease. J Sex Med 2010; 7 (4 Pt 1): 1529–1537.

27. Kadioglu A, Tefekli A, Erol B et al. A retrospective review of 307 men with Peyronie’s disease. J Urol 2002; 168(3): 1075–1079.

28. Carrieri MP, Serraino D, Palmiotto F et al. A case-control study on risk factors for Peyronie’s disease. J Clin Epidemiol 1998; 51(6): 511–515.

28. Deveci S, Hopps CV, O’Brien K et al. Defining the clinical characteristics of Peyronie’s disease in young men. J Sex Med 2007; 4(2): 485–490.

30. Bjekic MD, Vlajinac HD, Sipetic SB et al. Risk factors for Peyronie’s disease: a case-control study. BJU Int 2006; 97(3): 570–574.

31. Tal R, Heck M, Teloken P et al. Peyronie’s disease following radical prostatectomy: incidence and predictors. J Sex Med 2010; 7(3): 1254–1261.

32. Ralph D, Gonzalez-Cadavid N, Mirone V et al. The management of Peyronie’s disease: evidencebased 2010 guidelines. J Sex Med 2010; 7(7): 2359–2374.

33. Gelbard MK, Dorey F, James K. The natural his­tory of Peyronie’s disease. J Urol 1990; 144(6): 1376–1379.

34. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie’s disease. J Urol 2006; 175(6): 2115–2118.

35. Bekos A, Arvaniti M, Hatzimouratidis K et al. The natural history of Peyronie’s disease: an ultrasono­graphy-based study. Eur Urol 2008; 53(3): 644–650.

36. Pryor JP, Ralph DJ. Clinical presentations of Peyro­nie’s disease. Int J Impot Res 2002; 14: 414–417.

37. Nelson CJ, Diblasio C, Kendirci M et al. The chro­no­logy of depression and distress in men with Peyro­nie’s disease. J Sex Med 2008; 5(8): 1985–1990.

38. Levine LA, Greenfield JM. Establishing a standar­dized evaluation of the man with Peyronie’s disease. Int J Impot Res 2003; 15 (Suppl 5): S103–S112.

39. Greenfield JM, Lucas S, Levine LA. Factors affec­ting the loss of length associated with tunica albugi­nea plication for correction of penile curvature. J Urol 2006; 175(1): 238–241.

40. Rosen RC, Riley A, Wagner G et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49(6): 822–830.

41. Kadioglu A, Tefekli A, Erol H et al. Color Doppler ultrasound assessment of penile vascular system in men with Peyronie’s disease. Int J Impot Res 2000; 12(5): 263–267.

42. Porst H, Vardi Y, Akkus E et al. Standards for cli­nical trials in male sexual dysfunctions. J Sex Med 2010; 7 (1 Pt 2): 414–444.

43. Hellstrom WJ, Bivalacqua TJ. Peyronie’s disease: etiology, medical, and surgical therapy. J Androl 2000; 21(3): 347–354.

44. Muller A, Mulhall JP. Peyronie’s disease intervention trials: methodological challenges and issues. J Sex Med 2009; 6(3): 848–861.

45. Shindel AW, Bullock TL, Brandes S. Urologist practice patterns in the management of Peyronie’s disease: a nationwide survey. J Sex Med 2008; 5(4): 954–964.

46. Scott WW, Scardino PL. A new concept in the treatment of Peyronie’s disease. South Med J 1948; 41(2): 173–177.

47. Pryor JP, Farell CF. Controlled clinical trial of Vita­min E in Peyronie’s disease. Prog Reprod Biol 1983; 9: 41–45.

48. Griffiths MR, Priestley GC. A comparison of morphoea and lichen sclerosus et atrophicus in vitro: the effects of para-aminobenzoate on skin fibroblasts. Acta Derm Venereol 1992; 72(1): 15–18.

49. Zarafonetis CJ, Horrax TM. Treatment of Peyro­nie’s disease with potassium para-aminobenzoate (potaba). J Urol 1959; 81(6): 770–772.

50. Shah PJR, Green NA, Adib RS et al. A multicentre double-blind controlled clinical trial of potassium para-amino-benzoate (POTABA1) in Peyronie’s disease. Progr Reprod Biol Med 1983; 9: 61–67.

51. Weidner W, Hauck EW, Schnitker J. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized study. Eur Urol 2005; 47(4): 530–535.

52. Ralph DJ, Brooks MD, Bottazzo GF et al. The treatment of Peyronie’s disease with tamoxifen. Br J Urol 1992; 70(6): 648–651.

53. Teloken C, Rhoden EL, Grazziotin TM et al. Tamo­xifen versus placebo in the treatment of Peyronie’s disease. J Urol 1999; 162(6): 2003–2005.

54. Kadioglu A, Tefekli A, Koksal T et al. Treatment of Peyronie’s disease with oral colchicine: long-term results and predictive parameters of successful outcome. Int J Impot Res 2000; 12(3): 169–175.

55. Akkus E, Carrier S, Rehman J et al. Is colchicine effective in Peyronie’s disease? A pilot study. Urology 1994; 44(2): 291–295.

56. Akman T, Sanli O, Uluocak N et al. The most commonly altered type of Peyronie’s disease deformity under oral colchicine treatment is lateral curvature that mostly shifts to the dorsal side. Andrologia 2011; 43(1): 28–33.

57. Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC et al. Combined treatment with vitamin E and colchicine in the early stages of Peyronie’s disease. BJU Int 2003; 91(6): 522–524.

58. Netticadan T, Yu L, Dhalla NS et al. Palmitoyl carni­tine increases intracellular calcium in adult rat cardio­myocytes. J Mol Cell Cardiol 1999; 31(7): 1357–1367.

59. Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamo­xifen in the oral therapy of Peyronie’s disease: a preliminary report. BJU Int 2001; 88(1): 63–67.

60. Cavallini G, Biagiotti G, Koverech A et al. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie’s disease. BJU Int 2002; 89(9): 895–900.

61. Shindel AW, Lin G, Ning H et al. Pentoxifylline attenuates transforming growth factor-beta1- stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix. J Sex Med 2010; 7(6): 2077–2085.

62. Brant WO, Dean RC, Lue TF. Treatment of Peyro­nie’s disease with oral pentoxifylline. Nat Clin Pract Urol 2006; 3(2): 111–115.

63. Smith JF, Shindel AW, Huang YC et al. Pento­xify­l­line treatment and penile calcifications in men with Peyro­nie’s disease. Asian J Androl 2011; 13(2): 322–325.

64. Ferrini MG, Kovanecz I, Nolazco G et al. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie’s disease. BJU Int 2006; 97(3): 625–633.

65. Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med 2011; 8(5): 1472–1477.

66. Tranchant C, Braun S, Warter JM. Mechanism of action of glucocorticoids: role of lipocortins. Rev Neurol (Paris) 1989; 145(12): 813–818.

67. Desanctis PN, Furey CA Jr. Steroid injection the­rapy for Peyronie’s disease: a 10-year summary and review of 38 cases. J Urol 1967; 97(1): 114–116.

68. Winter CC, Khanna R. Peyronie’s disease: results with dermo-jet injection of dexamethasone. J Urol 1975; 114(6): 898–900.

69. Cipollone G, Nicolai M, Mastroprimiano G et al. Beta­methasone versus placebo in Peyronie’s disease. Arch Ital Urol Androl 1998; 70(4): 165–168.

70. Roth M, Eickelberg O, Kohler E et al. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci U S A 1996; 93(11): 5478–5482.

71. Mulhall JP, Anderson MS, Lubrano T et al. Peyro­nie’s disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res 2002; 14(5): 397–405.

72. Levine LA, Goldman KE, Greenfield JM. Expe­rience with intraplaque injection of verapamil for Peyronie’s disease. J Urol 2002; 168(2): 621–625.

73. Anderson MS, Shankey TV, Lubrano T et al. Inhibition of Peyronie’s plaque fibroblast proliferation by biologic agents. Int J Impot Res 2000; 12 (Suppl 3): S25–S31.

74. Rehman J, Benet A, Melman A. Use of intralesio­nal verapamil to dissolve Peyronie’s disease plaque: a long-term single-blind study. Urology 1998; 51(4): 620–626.

75. Bennett NE, Guhring P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie’s disease. Urology 2007; 69(6): 1181–1184.

76. Cavallini G, Modenini F, Vitali G. Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie’s disease. Urology 2007; 69(5): 950–954.

77. Shirazi M, Haghpanah AR, Badiee M et al. Effect of intralesional verapamil for treatment of Peyronie’s disease: a randomized single-blind, placebo-controlled study. Int Urol Nephrol 2009; 41(3): 467–471.

78. Moskovic DJ, Alex B, Choi JM et al. Defining predic­tors of response to intralesional verapamil injection therapy for Peyronie’s disease. BJU Int 2011; 108(9): 1485–1489.

79. Gelbard MK, James K, Riach P et al. Collagenase ver­sus placebo in the treatment of Peyronie’s disease: a double-blind study. J Urol 1993; 149(1): 56–58.

80. Ehrlich HP. Scar contracture: cellular and connective tissue aspects in Peyronie’s disease. J Urol 1997; 157(1): 316–319.

81. Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie’s disease: a prospective, single-center, non-placebo-controlled study. J Sex Med 2008; 5(1): 180–187.

82. Hurst LC, Badalamente MA, Hentz VR et al. Injec­table collagenase clostridium histolyticum for Dupuy­tren’s contracture. N Engl J Med 2009; 361(10): 968–979.

83. Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie’s disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol 1991; 25(2): 89–94.

84. Kendirci M, Usta MF, Matern RV et al. The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie’s disease. J Sex Med 2005; 2(5): 709–715.

85. Hellstrom WJ, Kendirci M, Matern R et al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie’s disease. J Urol 2006; 176(1): 394–398.

86. Fitch WP 3rd, Easterling WJ, Talbert RL et al. Topical verapamil HCl, topical trifluoperazine, and to­pical magnesium sulfate for the treatment of Peyronie’s disease - a placebo-controlled pilot study. J Sex Med 2007; 4(2): 477–484.

87. Martin DJ, Badwan K, Parker M et al. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 2002; 168(6): 2483–2485.

88. Di Stasi SM, Giannantoni A, Capelli G et al. Trans­dermal electromotive administration of verapamil and dexamethasone for Peyronie’s disease. BJU Int 2003; 91(9): 825–829.

89. Riedl CR, Plas E, Engelhardt P et al. Iontophoresis for treatment of Peyronie’s disease. J Urol 2000; 163(1): 95–99.

90. Tuygun C, Ozok UH, Gucuk A et al. The effectiveness of transdermal electromotive administration with verapamil and dexamethasone in the treatment of Pey­ronie’s disease. Int Urol Nephrol 2009; 41(1): 113–118.

91. Di Stasi SM, Giannantoni A, Stephen RL et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexa­methasone for Peyronie’s disease. J Urol 2004; 171(4): 1605–1608.

92. Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie’s disease: a double-blind, placebo controlled trial. J Urol 2007; 177(3): 972–975.

93. Husain J, Lynn NN, Jones DK et al. Extracorporeal shock wave therapy in the management of Peyronie’s disease: initial experience. BJU Int 2000; 86(4): 466–468.

94. Strebel RT, Suter S, Sautter T et al. Extracorporeal shockwave therapy for Peyronie’s disease does not correct penile deformity. Int J Impot Res 2004; 16(5): 448–451.

95. Hauck EW, Hauptmann A, Bschleipfer T et al. Questionable efficacy of extracorporeal shock wave therapy for Peyronie’s disease: results of a prospective approach. J Urol 2004; 171(1): 296–299.

96. Srirangam SJ, Manikandan R, Hussain J et al. Long-term results of extracorporeal shockwave therapy for Peyronie’s disease. J Endourol 2006; 20(11): 880–884.

97. Palmieri A, Imbimbo C, Longo N et al. A first prospective, randomized, double-blind, placebo controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie’s disease. Eur Urol 2009; 56(2): 363–369.

98. Bailey AJ, Tarlton JF, Van der Stappen J et al. The continuous elongation technique for severe Du­puytren’s disease. A biochemical mechanism. J Hand Surg Br 1994; 19(4): 522–527.

99. Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie’s disease: a singlecenter pilot study. J Sex Med 2008; 5(6): 1468–1473.

100. Gontero P, Di Marco M, Giubilei G et al. Use of penile extender device in the treatment of penile curvature as a result of Peyronie’s disease. Results of a phase II prospective study. J Sex Med 2009; 6(2): 558–566.

101. Raheem AA, Garaffa G, Raheem TA et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie’s disease. BJU Int 2010; 106(8): 1178–1180.

102. Montorsi F, Adaikan G, Becher E et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2010; 7(11): 3572–3588.

103. Kendirci M, Hellstrom WJ. Critical analysis of surgery for Peyronie’s disease. Curr Opin Urol 2004; 14: 381–388.

104. Langston JP, Carson CC 3rd. Peyronie disease: plication or grafting. Urol Clin North Am 2011; 38: 207–216.

105. Garaffa G, Sacca A, Christopher AN et al. Circum­cision is not mandatory in penile surgery. BJU Int 2010; 105(2): 222–224.

106. Mulhall J, Anderson M, Parker M. A surgical algorithm for men with combined Peyronie’s disease and erectile dysfunction: functional and satisfaction outcomes. J Sex Med 2005; 2(1): 132–138.

107. Smith JF, Walsh TJ, Lue TF. Peyronie’s disease: a critical appraisal of current diagnosis and treatment. Int J Impot Res 2008; 20(5): 445–459.

108. Pryor JP, Fitzpatrick JM. A new approach to the correction of the penile deformity in Peyronie’s disease. J Urol 1979; 122(5): 622–623.

109. Pryor JP. Correction of penile curvature and Peyronie’s disease: why I prefer the Nesbit technique. Int J Impot Res 1998; 10(2): 129–131.

110. Ralph DJ, al-Akraa M, Pryor JP. The Nesbit ope­ra­tion for Peyronie’s disease: 16-year experience. J Urol 1995; 154(4): 1362–1363.

111. Savoca G, Trombetta C, Ciampalini S et al. Long-term results with Nesbit’s procedure as treatment of Peyronie’s disease. Int J Impot Res 2000; 12(5): 289–2893.

112. Rehman J, Benet A, Minsky LS et al. Results of surgical treatment for abnormal penile curvature: Peyronie’s disease and congenital deviation by modified Nesbit plication (tunical shaving and plication). J Urol 1997; 157(4): 1288–1291.

113. Lemberger RJ, Bishop MC, Bates CP. Nesbit’s operation for Peyronie’s disease. Br J Urol 1984; 56(6): 721–723.

114. Sassine AM, Wespes E, Schulman CC. Modified corporoplasty for penile curvature: 10 years’ experience. Urology 1994; 44(3): 419–421.

115. Licht MR, Lewis RW. Modified Nesbit procedure for the treatment of Peyronie’s disease: a comparative outcome analysis. J Urol 1997; 158(2): 460–463.

116. Yachia D. Modified corporoplasty for the treatment of penile curvature. J Urol 1990; 143(1): 80–82.

117. Essed E, Schroeder FH. New surgical treatment for Peyronie disease. Urology 1985; 25(6): 582–587.

118. Ebbehoj J, Metz P. New operation for “krummerik” (penile curvature). Urology 1985; 26(1): 76–78.

119. Gholami SS, Lue TF. Correction of penile curvature using the 16-dot plication technique: a review of 132 patients. J Urol 2002; 167(5): 2066–2069.

120. Dalkin BL, Carter MF. Venogenic impotence following dermal graft repair for Peyronie’s disease. J Urol 1991; 146(3): 849–851.

121. Devine CJ Jr, Horton CE. Surgical treatment of Peyronie’s disease with a dermal graff. J Urol 1974; 111(1): 44–49.

122. Montorsi F, Salonia A, Maga T et al. Evidence based assessment of long-term results of plaque incision and vein grafting for Peyronie’s disease. J Urol 2000; 163(6): 1704–1708.

123. Kadioglu A, Tefekli A, Usta M et al. Surgical treatment of Peyronie’s disease with incision and venous patch technique. Int J Impot Res 1999; 11(2): 75–81.

124. El-Sakka AI, Rashwan HM, Lue TF. Venous patch graft for Peyronie’s disease. Part II: outcome analysis. J Urol 1998; 160 (6 Pt 1): 2050–2053.

125. Hatzichristou DG, Hatzimouratidis K, Apostolidis A et al. Corporoplasty using tunica albuginea free grafts for penile curvature: surgical technique and long-term results. J Urol 2002; 167(3): 1367–1370.

126. Das S. Peyronie’s disease: excision and autografting with tunica vaginalis. J Urol 1980; 124(6): 818–819.

127. Gelbard MK, Hayden B. Expanding contractures of the tunica albuginea due to Peyronie’s disease with temporalis fascia free grafts. J Urol 1991; 145(4): 772–776.

128. Cormio L, Zucchi A, Lorusso F et al. Surgical treatment of Peyronie’s disease by plaque incision and grafting with buccal mucosa. Eur Urol 2009; 55(6): 1469–1475.

129. Taylor FL, Levine LA. Surgical correction of Peyronie’s disease via tunica albuginea plication or partial plaque excision with pericardial graft: long-term follow up. J Sex Med 2008; 5(9): 2221–2228.

130. Burnett AL. Fascia lata in penile reconstructive surgery: a reappraisal of the fascia lata graft. Plast Reconstr Surg 1997; 99(4): 1061–1067.

131. Fallon B. Cadaveric dura mater graft for correction of penile curvature in Peyronie disease. Urology 1990; 35(2): 127–129.

132. Leungwattanakij S, Bivalacqua TJ, Yang DY et al. Comparison of cadaveric pericardial, dermal, vein, and synthetic grafts for tunica albuginea substitution using a rat model. BJU Int 2003; 92(1): 119–124.

133. Knoll LD. Use of porcine small intestinal submucosal graft in the surgical management of Peyronie’s disease. Urology 2001; 57(4): 753–757.

134. Bokarica P, Parazajder J, Mazuran B et al. Surgical treatment of Peyronie’s disease based on penile length and degree of curvature. Int J Impot Res 2005; 17(2): 170–174.

135. Faerber GJ, Konnak JW. Results of combined Nesbit penile plication with plaque incision and placement of Dacron patch in patients with severe Peyronie’s disease. J Urol 1993; 149 (5 Pt 2): 1319–1320.

136. Egydio PH, Lucon AM, Arap S. A single relaxing incision to correct different types of penile curvature: surgical technique based on geometrical principles. BJU Int 2004; 94(7): 1147–1157.

137. Kadioglu A, Akman T, Sanli O et al. Surgical treatment of Peyronie’s disease: a critical analysis. Eur Urol 2006; 50(2): 235–248.

138. Chun JL, McGregor A, Krishnan R et al. A comparison of dermal and cadaveric pericardial grafts in the modified Horton-Devine procedure for Peyronie’s disease. J Urol 2001; 166(1): 185–188.

139. Chung E, Clendinning E, Lessard L et al. Five-year follow-up of Peyronie’s graft surgery: outcomes and patient satisfaction. J Sex Med 2011; 8(2): 594–600.

140. Taylor FL, Levine LA. Peyronie’s Disease. Urol Clin North Am 2007; 34(4): 517–534.

141. Montorsi F, Guazzoni G, Barbieri L et al. AMS 700 CX inflatable penile implants for Peyronie’s disease: functional results, morbidity and patient-partner satisfaction. Int J Impot Res 1996; 8(2): 81–85.

142. Wilson SK. Surgical techniques: modeling technique for penile curvature. J Sex Med 2007; 4(1): 231–234.

143. Wilson SK, Delk JR 2nd. A new treatment for Peyronie’s disease: modeling the penis over an inflatable penile prosthesis. J Urol 1994; 152(4): 1121–1123.

144. Carson CC. Penile prosthesis implantation in the treatment of Peyronie’s disease. Int J Impot Res 1998; 10(2): 125–128.

145. Montague DK, Angermeier KW, Lakin MM et al. AMS 3-piece inflatable penile prosthesis implantation in men with Peyronie’s disease: comparison of CX and Ultrex cylinders. J Urol 1996; 156(5): 1633–1635.

146. Chaudhary M, Sheikh N, Asterling S et al. Peyro­nie’s disease with erectile dysfunction: penile modelling over inflatable penile prostheses. Urology 2005; 65(4): 760–764.